FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617371007> ?p ?o ?g. }

• W2617371007 endingPage "1511" @default.
• W2617371007 startingPage "1500" @default.
• W2617371007 abstract "Neutropenic enterocolitis (NEC) is an abdominal infection reported primarily in patients with acute myeloid leukemia (AML) following chemotherapy, especially cytarabine, a notable efficacious cytotoxic agent for AML remission. Specific data regarding the impact of different cytarabine schedules and/or antibacterial regimens for NEC are sparse. The aim of the study was to identify the predictors of outcome within 30 days of NEC onset. NEC episodes were retrospectively pinpointed among 440 patients with newly diagnosed AML hospitalized in our Institution, over a 10-year period, for receiving chemotherapy protocols with 100–6000 mg/m2 daily of cytarabine. Two subgroups, survivors versus nonsurvivors, were compared by using logistic regression analysis. NEC was documented in 100 of 420 (23.8%) analyzed patients: 42.5% had received high-dose cytarabine, whereas 19% and 15% intermediate-dose and standard-dose cytarabine, respectively (P < 0.001). The 30-day NEC attributable mortality rate was 23%. In univariate analysis, antileukemic protocols containing robust dosages of cytarabine were significantly associated with high mortality (P < 0.001); whereas, standard-dose cytarabine and prompt initiation (at the ultrasonographic appearance of intestinal mural thickening) of NEC therapy with antibiotic combinations including tigecycline were significantly associated with low mortality. In multivariate analysis, high-dose cytarabine-containing chemotherapy was the independent predictor of poor outcome (odds ratio [OR]: 0.109; 95% confidence interval [CI]: 0.032–0.364; P < 0.001), whereas ultrasonography-driven NEC therapy with antibiotic regimens including tigecycline was associated with a favorable outcome (OR: 13.161; 95% CI: 1.587–109.17; P = 0.017). Chemotherapy schedules with robust dosages of cytarabine for AML remission are associated with a high rate of NEC incidence and attributable. Vigorous antibacterial therapy, triggered off pathologic ultrasonographic findings, with drug combinations which have broad antimicrobial coverage and good gut penetration, specifically those also including tigecycline, may be effective in improving 30-day survival rate after NEC onset." @default.
• W2617371007 created "2017-06-05" @default.
• W2617371007 creator A5004150120 @default.
• W2617371007 creator A5005922904 @default.
• W2617371007 creator A5016280304 @default.
• W2617371007 creator A5021796081 @default.
• W2617371007 creator A5038607756 @default.
• W2617371007 creator A5043336565 @default.
• W2617371007 creator A5047732268 @default.
• W2617371007 creator A5057031849 @default.
• W2617371007 creator A5057084037 @default.
• W2617371007 creator A5059488532 @default.
• W2617371007 creator A5079701837 @default.
• W2617371007 creator A5083968415 @default.
• W2617371007 creator A5086760651 @default.
• W2617371007 date "2017-05-26" @default.
• W2617371007 modified "2023-10-18" @default.
• W2617371007 title "Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia" @default.
• W2617371007 cites W103788795 @default.
• W2617371007 cites W1575991619 @default.
• W2617371007 cites W1853332726 @default.
• W2617371007 cites W1980574916 @default.
• W2617371007 cites W1985172346 @default.
• W2617371007 cites W1991721421 @default.
• W2617371007 cites W1997571080 @default.
• W2617371007 cites W1999156712 @default.
• W2617371007 cites W2010026460 @default.
• W2617371007 cites W2016059561 @default.
• W2617371007 cites W2050291056 @default.
• W2617371007 cites W2070483538 @default.
• W2617371007 cites W2071342876 @default.
• W2617371007 cites W2087203965 @default.
• W2617371007 cites W2096598041 @default.
• W2617371007 cites W2102891951 @default.
• W2617371007 cites W2104541470 @default.
• W2617371007 cites W2112998845 @default.
• W2617371007 cites W2117844516 @default.
• W2617371007 cites W2136450019 @default.
• W2617371007 cites W2137602673 @default.
• W2617371007 cites W2148049958 @default.
• W2617371007 cites W2150845402 @default.
• W2617371007 cites W2156546371 @default.
• W2617371007 cites W2160746673 @default.
• W2617371007 cites W2141983127 @default.
• W2617371007 doi "https://doi.org/10.1002/cam4.1063" @default.
• W2617371007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5504336" @default.
• W2617371007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28556623" @default.
• W2617371007 hasPublicationYear "2017" @default.
• W2617371007 type Work @default.
• W2617371007 sameAs 2617371007 @default.
• W2617371007 citedByCount "12" @default.
• W2617371007 countsByYear W26173710072018 @default.
• W2617371007 countsByYear W26173710072019 @default.
• W2617371007 countsByYear W26173710072021 @default.
• W2617371007 countsByYear W26173710072022 @default.
• W2617371007 countsByYear W26173710072023 @default.
• W2617371007 crossrefType "journal-article" @default.
• W2617371007 hasAuthorship W2617371007A5004150120 @default.
• W2617371007 hasAuthorship W2617371007A5005922904 @default.
• W2617371007 hasAuthorship W2617371007A5016280304 @default.
• W2617371007 hasAuthorship W2617371007A5021796081 @default.
• W2617371007 hasAuthorship W2617371007A5038607756 @default.
• W2617371007 hasAuthorship W2617371007A5043336565 @default.
• W2617371007 hasAuthorship W2617371007A5047732268 @default.
• W2617371007 hasAuthorship W2617371007A5057031849 @default.
• W2617371007 hasAuthorship W2617371007A5057084037 @default.
• W2617371007 hasAuthorship W2617371007A5059488532 @default.
• W2617371007 hasAuthorship W2617371007A5079701837 @default.
• W2617371007 hasAuthorship W2617371007A5083968415 @default.
• W2617371007 hasAuthorship W2617371007A5086760651 @default.
• W2617371007 hasBestOaLocation W26173710071 @default.
• W2617371007 hasConcept C126322002 @default.
• W2617371007 hasConcept C141071460 @default.
• W2617371007 hasConcept C156957248 @default.
• W2617371007 hasConcept C2776694085 @default.
• W2617371007 hasConcept C2777027569 @default.
• W2617371007 hasConcept C2778041864 @default.
• W2617371007 hasConcept C44249647 @default.
• W2617371007 hasConcept C501593827 @default.
• W2617371007 hasConcept C71924100 @default.
• W2617371007 hasConcept C86803240 @default.
• W2617371007 hasConcept C89423630 @default.
• W2617371007 hasConcept C90924648 @default.
• W2617371007 hasConceptScore W2617371007C126322002 @default.
• W2617371007 hasConceptScore W2617371007C141071460 @default.
• W2617371007 hasConceptScore W2617371007C156957248 @default.
• W2617371007 hasConceptScore W2617371007C2776694085 @default.
• W2617371007 hasConceptScore W2617371007C2777027569 @default.
• W2617371007 hasConceptScore W2617371007C2778041864 @default.
• W2617371007 hasConceptScore W2617371007C44249647 @default.
• W2617371007 hasConceptScore W2617371007C501593827 @default.
• W2617371007 hasConceptScore W2617371007C71924100 @default.
• W2617371007 hasConceptScore W2617371007C86803240 @default.
• W2617371007 hasConceptScore W2617371007C89423630 @default.
• W2617371007 hasConceptScore W2617371007C90924648 @default.
• W2617371007 hasFunder F4320324043 @default.
• W2617371007 hasIssue "7" @default.
• W2617371007 hasLocation W26173710071 @default.

• next